Building a leading retinal therapeutics franchise
Our high-value, near-term pipeline uses our innovative technology to create differentiated product candidates with the potential to transform the treatment paradigm for retinal disorders.
Building a leading retinal therapeutics franchise
Our high-value, near-term pipeline uses our innovative technology to create differentiated product candidates with the potential to transform the treatment paradigm for retinal disorders.
Part A
An open-label, randomized study comparing two dose levels of sustained-release suprachoroidal OXU-001 (DEXAspheres®), administered with the Oxulumis® illuminated microcatheterization device, in people with Diabetic Macular Edema.
Part A
An open-label, randomized study comparing two dose levels of sustained-release suprachoroidal OXU-001 (DEXAspheres®), administered with the Oxulumis® illuminated microcatheterization device, in people with Diabetic Macular Edema.
